Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

See hackaday.io page for screenshots. Qwt is the library that provides plotting widgets for SerialPlot. You have 3 different options for Qwt. Leave it to serialplot ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ ... heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, to be filed with the ...

A trend in gene therapy setbacks continues as Vertex Pharmaceuticals gave Verve Therapeutics back the rights to a liver disease gene editing program. The research and development deal dates back to ...

According to reports, Arsenal have hatched a plan to ‘form the most feared attack in the Premier League’ as they have identified their two top targets. The Gunners are crying out for a new ...